BSE Live
Dec 24, 16:01Prev. Close
1216.80
Open Price
1216.80
Bid Price (Qty.)
1208.00 (30)
Offer Price (Qty.)
1214.00 (447)
NSE Live
Dec 24, 15:55Prev. Close
1218.00
Open Price
1220.90
Bid Price (Qty.)
1211.40 (15)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 48.32 | 40.36 | 41.36 | 39.33 | 34.67 | |
| Diluted EPS (Rs.) | 48.32 | 40.36 | 41.36 | 39.33 | 34.66 | |
| Cash EPS (Rs.) | 65.05 | 51.71 | 50.82 | 46.49 | 41.26 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 286.92 | 237.11 | 199.39 | 159.99 | 124.57 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 286.92 | 237.11 | 199.39 | 159.99 | 124.57 | |
| Revenue from Operations/Share (Rs.) | 394.24 | 333.91 | 280.99 | 254.47 | 235.73 | |
| PBDIT/Share (Rs.) | 86.30 | 70.10 | 66.12 | 60.59 | 57.96 | |
| PBIT/Share (Rs.) | 69.80 | 58.70 | 56.59 | 53.29 | 51.26 | |
| PBT/Share (Rs.) | 64.14 | 52.72 | 55.27 | 52.16 | 46.87 | |
| Net Profit/Share (Rs.) | 48.55 | 40.31 | 41.30 | 39.19 | 34.55 | |
| NP After MI And SOA / Share (Rs.) | 48.32 | 40.36 | 41.36 | 39.28 | 34.61 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 21.88 | 20.99 | 23.52 | 23.81 | 24.58 | |
| PBIT Margin (%) | 17.70 | 17.58 | 20.14 | 20.94 | 21.74 | |
| PBT Margin (%) | 16.27 | 15.78 | 19.66 | 20.49 | 19.88 | |
| Net Profit Margin (%) | 12.31 | 12.07 | 14.69 | 15.40 | 14.65 | |
| NP After MI And SOA Margin (%) | 12.25 | 12.08 | 14.71 | 15.43 | 14.68 | |
| Return on Networth/Equity (%) | 16.84 | 17.02 | 20.74 | 24.55 | 27.78 | |
| Return on Capital Employed (%) | 23.31 | 23.82 | 26.66 | 32.37 | 37.12 | |
| Return on Assets (%) | 9.78 | 8.93 | 11.48 | 14.16 | 12.72 | |
| Total Debt/Equity (X) | 0.32 | 0.49 | 0.38 | 0.33 | 0.61 | |
| Asset Turnover Ratio (%) | 0.83 | 0.82 | 0.88 | 0.93 | 0.96 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.44 | 1.28 | 1.41 | 1.39 | 1.31 | |
| Quick Ratio (X) | 0.77 | 0.67 | 0.73 | 0.74 | 0.80 | |
| Inventory Turnover Ratio (X) | 1.03 | 1.14 | 1.10 | 1.24 | 1.26 | |
| Dividend Payout Ratio (NP) (%) | 6.20 | 6.19 | 9.06 | 4.95 | 6.63 | |
| Dividend Payout Ratio (CP) (%) | 4.62 | 4.83 | 7.36 | 4.18 | 5.55 | |
| Earnings Retention Ratio (%) | 93.80 | 93.81 | 90.94 | 95.05 | 93.37 | |
| Cash Earnings Retention Ratio (%) | 95.38 | 95.17 | 92.64 | 95.82 | 94.45 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 16.57 | 15.64 | 49.84 | 53.21 | 13.21 | |
| Interest Coverage Ratios (Post Tax) (%) | 16.57 | 15.64 | 49.84 | 53.21 | 13.21 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 26,780.89 | 50,849.31 | 35,871.39 | 42,129.76 | 47,215.18 | |
| EV/Net Operating Revenue (X) | 1.16 | 2.60 | 2.18 | 2.83 | 3.42 | |
| EV/EBITDA (X) | 5.30 | 12.38 | 9.26 | 11.87 | 13.92 | |
| MarketCap/Net Operating Revenue (X) | 1.05 | 2.35 | 1.98 | 2.65 | 3.16 | |
| Retention Ratios (%) | 93.79 | 93.80 | 90.93 | 95.04 | 93.36 | |
| Price/BV (X) | 1.44 | 3.32 | 2.80 | 4.22 | 5.98 | |
| Price/Net Operating Revenue | 1.05 | 2.35 | 1.98 | 2.65 | 3.16 | |
| Earnings Yield | 0.12 | 0.05 | 0.07 | 0.06 | 0.05 |
19.12.2025
15.12.2025
04.12.2025
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL